US2020188352A1PendingUtilityA1

Escalating dosing regimen for effecting weight loss and treating obesity

Assignee: VIVUS INCPriority: Jun 9, 2008Filed: Feb 20, 2020Published: Jun 18, 2020

Est. expiryJun 9, 2028(~1.9 yrs left)· nominal 20-yr term from priority

Inventors:Thomas Najarian Peter Y. Tam Leland F. Wilson

A61K 31/137A61K 31/35A61K 9/20A61P 3/04A61P 9/12A61K 47/38A61K 9/5073A61P 19/02A61K 31/7048A61P 15/00A61P 25/06A61P 11/00A61K 9/5084A61K 31/00A61K 31/135A61P 31/04A61K 9/4866A61K 9/1676A61K 31/357A61P 3/06A61P 25/00A61P 19/06A61P 35/00A61K 9/5026A61P 3/10A61K 9/1629A61K 9/5047A61P 1/08A61P 25/02A61K 9/167A61P 43/00A61P 9/10A61P 21/00A61P 25/20A61K 9/1623A61P 11/06A61K 9/5042

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.

Claims

exact text as granted — not AI-modified

1 . A controlled release composition for treating obesity, diabetes, sleep apnea, or a related condition in a subject comprising:
 an effective amount of topiramate and phentermine.   
     
     
         2 . A method for effecting weight loss in a subject, comprising administering to the subject continually over a significant period of time a daily dose of phentermine in combination therewith a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.